Automated Call vs Text Messaging: Number (%) Tested (Total and by Clinic)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00267 | 0.00153 | 0.00467 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0054 | 0.00366 | 0.00796 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00273 | -0.00553 | -0.0000796 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.495 | 0.249 | 0.984 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.494 | 0.248 | 0.984 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Automated Call than on Text Messaging | 367 | 181 | 12,600 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Automated Call | Patients receive up to two automated phone calls in English or Spanish depending the patients' language indicated in their electronic health record (EHR), between the hours of 10:00am and 9:00pm Monday through Friday.~Community outreach method: The method includes automated call and text messaging to increase testing for COVID-19 | 12 | 4,489 | OG000 | ClinicalTrials.gov |
| Group 2 | Text Messaging | Patients receive up to two text messages in English or Spanish depending the patients' language indicated in their electronic health record (EHR), between the hours of 10:00am and 9:00pm Monday through Friday.~Community outreach method: The method includes automated call and text messaging to increase testing for COVID-19 | 25 | 4,631 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number (%) Tested (Total and by Clinic) | ClinicalTrials.gov |
| Description | Number (%) of patients who complete COVID-19 test (total and by clinic) | ClinicalTrials.gov |
| Time frame | 1 month | ClinicalTrials.gov |
| Population | Because of extremely low testing uptake, slow accrual at participating health centers and continuously changing COVID pandemic, we were forced to terminate the intervention study and pivot to alternate strategies. This would allow us to continue our efforts to deliver as many COVID-19 tests as possible to help limit the spread of COVID-19 in underserved communities. Because of extremely low participants, there was no power to conduct statistical analysis for primary and secondary outcomes. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | COVID-19 Testing in Underserved and Vulnerable Populations | ClinicalTrials.gov |
| NCT number | NCT05315908 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases, COPD, Obesity, Sickle Cell Disease, Diabetes Mellitus, Type 2 | ClinicalTrials.gov |
| Interventions | Community outreach method | ClinicalTrials.gov |
| Lead sponsor | Jesse Nodora | ClinicalTrials.gov |
| Results first posted | 2024-02-28 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT05315908?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.